PROGLYCEM (diazoxide) by Teva is clinical pharmacology diazoxide produces a dose-related increase in blood glucose, due primarily to an inhibition of insulin release from the pancreas, and also to an extrapancreatic effect. First approved in 1976.
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
PROGLYCEM (diazoxide) is an oral small-molecule hyperglycemic agent approved in 1976 that raises blood glucose by inhibiting pancreatic insulin release and producing extrapancreatic metabolic effects. It is primarily used to manage hypoglycemia in patients with inoperable pancreatic tumors or those unable to tolerate other therapies. The drug's hyperglycemic effect begins within one hour and typically lasts up to eight hours with normal renal function.
Product is in late-stage lifecycle with moderate competitive pressure (30%), indicating a mature asset with potential consolidation or divestment activities ahead.
CLINICAL PHARMACOLOGY Diazoxide produces a dose-related increase in blood glucose, due primarily to an inhibition of insulin release from the pancreas, and also to an extrapancreatic effect. The hyperglycemic effect of diazoxide begins within an hour and generally lasts no more than eight hours in…
Worked on PROGLYCEM at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities
A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia
Diazoxide Choline in Hypertriglyceridemia
Teva is hiring 2 roles related to this product
Working on PROGLYCEM offers experience in niche/orphan specialty pharmaceuticals, complex reimbursement, and lifecycle management in a mature asset. Career advancement opportunities are limited as the product approaches loss of exclusivity, making this role best suited for professionals seeking deep expertise in a focused indication or preparing for transition to declining-asset management.